COCP Stock Summary and Trading Ideas (Cocrystal Pharma | NASDAQ:COCP)

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Cocrystal Pharma trades on the NASDAQ stock market under the symbol COCP.

As of June 4, 2026, COCP stock price declined to $1.05 with 162,434 million shares trading.

COCP has a beta of 1.48, meaning it tends to be more sensitive to market movements. COCP has a correlation of 0.06 to the broad based SPY ETF.

COCP has a market cap of $14.47 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, COCP traded as high as $3.29 and as low as $.86.

The top ETF exchange traded funds that COCP belongs to (by Net Assets): VTI, VXF.

COCP has underperformed the market in the last year with a price return of -37.5% while the SPY ETF gained +28.2%. COCP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.9% and -5.4%, respectively, while the SPY returned +11.5% and +2.1%, respectively.

COCP support price is $1.01 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COCP shares will trade within this expected range on the day.